Firstly, in real‐world studies, semaglutide has been associated with high rates of treatment discontinuation,32, 33 with 46.5% of individuals with T2D discontinuing GLP‐1 RA treatment within 1 year of initiation in a large US study of electronic medical records.33 Here, GLP1R is linked to type 2 diabetes mellitus.